Exhibit 99.1 Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies • Enrollment in Ntrust-2 expected to initiate by year-end 2024 • Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 • No further NKX019 development in lymphoma planned • Platform prioritized to focus on advancement of NKX019 for multiple autoimmune di ...